Original Article

You have full text access to this OnlineOpen article

Analysis of differential BRAFV600E mutational status in multifocal papillary thyroid carcinoma

Evidence of independent clonal origin in distinct tumor foci

  1. So Yeon Park MD1,2,
  2. Young Joo Park MD3,4,
  3. Yu Jin Lee MD4,
  4. Hyun Sook Lee BS5,
  5. Sung Hee Choi MD3,4,
  6. Gheeyoung Choe MD1,2,
  7. Hak-Chul Jang MD3,4,
  8. Seong Hoe Park MD2,
  9. Do Joon Park MD4,5,†,*,
  10. Bo Youn Cho MD4,5

Article first published online: 18 SEP 2006

DOI: 10.1002/cncr.22218

Issue

Cancer

Cancer

Volume 107, Issue 8, pages 1831–1838, 15 October 2006

Additional Information

How to Cite

Park, S. Y., Park, Y. J., Lee, Y. J., Lee, H. S., Choi, S. H., Choe, G., Jang, H.-C., Park, S. H., Park, D. J. and Cho, B. Y. (2006), Analysis of differential BRAFV600E mutational status in multifocal papillary thyroid carcinoma. Cancer, 107: 1831–1838. doi: 10.1002/cncr.22218

Author Information

  1. 1

    Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea

  2. 2

    Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

  3. 3

    Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea

  4. 4

    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

  5. 5

    Clinical Research Institute, Seoul National University Hospital, Seoul, Korea

  1. †

    Fax: (011) 82-2-762-9662

*Department of Internal Medicine, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea

Publication History

  1. Issue published online: 3 OCT 2006
  2. Article first published online: 18 SEP 2006
  3. Manuscript Accepted: 24 JUL 2006
  4. Manuscript Revised: 23 JUL 2006
  5. Manuscript Received: 4 APR 2006

Funded by

  • Seoul National University Bundang Hospital, Seongnam, Korea (Research Fund). Grant Number: 03-05-005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (247K)

REFERENCES

  • 1
    Iida F, Yonekura M, Miyakawa M. Study of intraglandular dissemination of thyroid cancer. Cancer. 1969; 24: 764–771.
    Direct Link:
  • 2
    Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer. 1985; 55: 805–828.
    Direct Link:
  • 3
    Russell WO, Ibanez ML, Clark RL, White EC. Thyroid carcinoma classification, intraglandular dissemination, and clinicopathological study based upon whole organ section of 80 glands. Cancer. 1963; 16: 1425–1460.
    Direct Link:
  • 4
    Katoh R, Sasaki J, Kurihara H, Suzuki K, Iida Y, Kawaoi A. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma: a clinicopathologic study of 105 consecutive patients. Cancer. 1992; 70: 1585–1590.
    Direct Link:
  • 5
    Mazzaferri EL, Jhiang S. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994; 97: 418–428.
  • 6
    Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment. Initial analysis of staging and outcome. Cancer. 1998; 83: 1012–1021.
    Direct Link:
  • 7
    Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998; 83: 4116–4122.
  • 8
    Moniz S, Catarino AL, Marques AR, Cavaco B, Sobrinho L, Leite V. Clonal origin of non-medullary thyroid tumours assessed by non-random X-chromosome inactivation. Eur J Endocrinol. 2002; 146: 27–33.
  • 9
    Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med. 2005; 352: 2406–2412.
  • 10
    Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990; 60: 557–563.
  • 11
    Bongarzone I, Butti MG, Coronelli S, et al. Frequent activation of RET protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res. 1994; 54: 2979–2985.
  • 12
    Pierotti MA, Bongarzone I, Borrello MG, et al. Rearrangements of TRK protooncogene in papillary thyroid carcinomas. J Endocrinol Invest. 1995; 18: 130–133.
  • 13
    Pierotti MA, Vigneri P, Bongarzone I. Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Recent Results Cancer Res. 1998; 154: 237–247.
  • 14
    Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95: 625–627.
  • 15
    Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003; 22: 6455–6457.
  • 16
    Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63: 1454–1457.
  • 17
    Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003; 63: 4561–4567.
  • 18
    Chung JH, Hahm JR, Min YK, et al. Detection of RET/PTC oncogene rearrangements in Korean papillary thyroid carcinomas. Thyroid. 1999; 9: 1237–1243.
  • 19
    Chung KW, Chang MC, Noh DY, Oh SK, Choe KJ, Yoon YK. RET oncogene expression of papillary thyroid carcinoma in Korea. Surg Today. 2004; 34: 485–492.
  • 20
    Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004; 45: 818–821.
  • 21
    Rosai J, Carcangiu ML, DeLellisn RA. Tumors of the Thyroid Gland. Washington, DC: Armed Forces Institute of Pathology; 1992.
  • 22
    Reinhoff WFJr. Lymphatic vessels of thyroid gland in dog and man. Arch Surg. 1931; 23: 783–804.
  • 23
    Middleton LP, Vlastos G, Mirza NQ, Eva S, Sahin AA. Multicentric mammary carcinoma: evidence of monoclonal proliferation. Cancer. 2002; 94: 1910–1916.
    Direct Link:
  • 24
    Namba H, Matsuo K, Fagin JA. Clonal composition of benign and malignant human thyroid tumors. J Clin Invest. 1990; 86: 120–125.
  • 25
    Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 1995; 95: 2047–2053.
  • 26
    Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005; 65: 4238–4245.
  • 27
    Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005; 12: 245–262.
  • 28
    Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with histologic types of papillary thyroid carcinoma. J Pathol. 2004; 202: 247–251.
    Direct Link:
  • 29
    Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch. 2005; 446: 589–595.
  • 30
    Sedliarou I, Saenko V, Lantsov D, et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol. 2004; 25: 1729–1735.
View Full Article (HTML) Get PDF (247K)